成人无症状性菌尿筛查:为美国预防服务工作组更新的证据报告与系统综述
该系统综述纳入19项研究(N=8443),评估成人(含妊娠期)无症状性菌尿筛查与治疗的获益与危害。妊娠期筛查与治疗与肾盂肾炎和低出生体重率降低相关,但证据不新(过去30年仅1项研究);非妊娠成人治疗未见获益,危害证据有限。
要点
- 妊娠期无症状性菌尿筛查与治疗与肾盂肾炎率降低相关(合并RR 0.24)。
- 妊娠期治疗与低出生体重率降低相关(合并RR 0.64),婴儿死亡率无显著差异。
- 非妊娠成人无症状性菌尿治疗未发现获益,筛查或治疗危害证据有限。
核心结论
- 妊娠期无症状性菌尿筛查与治疗与肾盂肾炎和低出生体重率降低相关,但现有证据不新,过去30年仅1项研究。
- 非妊娠成人无症状性菌尿治疗未发现获益,抗生素治疗危害的试验证据有限。
研究设计与样本
- 系统综述纳入随机临床试验和观察性研究,评估成人(含妊娠期)无症状性菌尿筛查与治疗的获益与危害。
- 共纳入19项研究(N=8443),由2名评价者独立进行批判性评估和数据提取,采用随机效应Meta分析。
主要发现
- 2项队列研究(n=5289)显示,筛查妊娠女性队列肾盂肾炎病例(0.5%)少于未筛查队列的回顾性比较(2.2%和1.8%),较大研究估计相对危险度为0.30(95%CI 0.15-0.60)。
- 妊娠期筛查与治疗的12项试验(n=2377;过去30年仅1项)显示肾盂肾炎率降低(干预组范围0%-16.5%,对照组范围2.2%-36.4%;合并RR 0.24,95%CI 0.14-0.40)。
- 妊娠期7项试验显示低出生体重率降低(干预组范围2.5%-14.8%,对照组范围6.7%-21.4%;合并RR 0.64,95%CI 0.46-0.90)。
- 妊娠期6项试验显示婴儿死亡率无显著差异(合并RR 0.98,95%CI 0.29-3.26)。
- 非妊娠成人无症状性菌尿治疗的5项随机临床试验(n=777)未报告感染风险、活动能力或死亡率的显著差异。
关键数值与推荐
- 妊娠期无症状性菌尿筛查与治疗:肾盂肾炎合并RR 0.24(95%CI 0.14-0.40;12项试验)。
- 妊娠期无症状性菌尿筛查与治疗:低出生体重合并RR 0.64(95%CI 0.46-0.90;7项试验)。
- 妊娠期无症状性菌尿筛查与治疗:婴儿死亡率合并RR 0.98(95%CI 0.29-3.26;6项试验)。
- 非妊娠成人无症状性菌尿治疗:5项随机临床试验(n=777)未报告感染风险、活动能力或死亡率的显著差异。
- 筛查或治疗危害的有限证据未发现统计学显著差异。
临床怎么用
- 妊娠期无症状性菌尿筛查与治疗与肾盂肾炎和低出生体重率降低相关,但现有证据不新,过去30年仅1项研究。
- 非妊娠成人无症状性菌尿治疗未发现获益。
- 抗生素治疗无症状性菌尿的危害试验证据有限。
局限性
- 现有证据不新,过去30年仅1项研究。
- 筛查或治疗危害的有限证据可用。
- 非妊娠成人无症状性菌尿治疗的试验证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Screening for asymptomatic bacteriuria can identify patients for whom treatment might be beneficial for preventing symptomatic infection and other health outcomes. OBJECTIVE: To systematically review benefits and harms of asymptomatic bacteriuria screening and treatment in adults, including during pregnancy, to inform the US Preventive Services Task Force. DATA SOURCES: MEDLINE, PubMed (publisher-supplied records), and Cochrane Collaboration Central Registry of Controlled Trials; surveillance through May 24, 2019. STUDY SELECTION: Randomized clinical trials (RCTs) and observational studies on benefits and harms of screening for asymptomatic bacteriuria; RCTs on benefits and harms of asymptomatic bacteriuria treatment. Eligible populations included unselected, asymptomatic individuals without known urinary tract conditions. DATA EXTRACTION AND SYNTHESIS: Independent critical appraisal and data abstraction by 2 reviewers. Random-effects meta-analysis was conducted to estimate benefits of the interventions. MAIN OUTCOMES AND MEASURES: Symptomatic infection; function, morbidity, mortality; pregnancy complications and birth outcomes. RESULTS: Nineteen studies (N = 8443) meeting inclusion criteria were identified. Two cohort studies (n = 5289) found fewer cases of pyelonephritis in the cohorts of screened pregnant women (0.5%) than within retrospective comparisons of unscreened cohorts (2.2% and 1.8%); the larger study estimated a statistically significant relative risk of 0.30 (95% CI, 0.15-0.60). No studies examined screening in nonpregnant populations. Among 12 trials of asymptomatic bacteriuria screening and treatment during pregnancy (n = 2377; 1 conducted within past 30 years), there were reduced rates of pyelonephritis (range, 0%-16.5% for the intervention group and 2.2%-36.4% for the control group; pooled risk ratio [RR], 0.24 [95% CI, 0.14-0.40]; 12 trials) and low birth weight (range, 2.5%-14.8% for the intervention group and 6.7%-21.4% for the control group; pooled RR, 0.64 [95% CI, 0.46-0.90]; 7 trials). There was no significant difference in infant mortality (pooled RR, 0.98 [95% CI, 0.29-3.26]; 6 trials). Five RCTs of asymptomatic bacteriuria treatment in nonpregnant adults (n = 777) did not report any significant differences in risk of infection, mobility, or mortality. Limited evidence on harms of screening or treatment was available, and no statistically significant differences were identified. CONCLUSIONS AND RELEVANCE: Screening and treatment for asymptomatic bacteriuria during pregnancy was associated with reduced rates of pyelonephritis and low birth weights, but the available evidence was not current, with only 1 study conducted in the past 30 years. Benefits of asymptomatic bacteriuria treatment in nonpregnant adult populations were not found. Trial evidence on harms of asymptomatic bacteriuria antibiotic treatment was limited.
引用
- Henderson JT, Webber EM, Bean SI, et al. Screening for Asymptomatic Bacteriuria in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2019. PMID: 31550037. doi:10.1001/jama.2019.10060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。